Published in

Wiley, Journal of Leukocyte Biology, 5(87), p. 943-948, 2010

DOI: 10.1189/jlb.1109713

Links

Tools

Export citation

Search in Google Scholar

A proinsulin74-90 -derived protease-resistant, altered peptide ligand increases TGF-β1 secretion in PBMC from patients with type 1 diabetes mellitus

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Proinsulin-based protease-resistant altered peptide ligands modulate proinsulin-reactive T cells to secret the anti-inflammatory cytokine TGF-β1. Proinsulin is a major diabetes-associated autoantigen. APL have been shown to manipulate the immune response of T cells. Here, we generated a lysosomal protease-resistant proinsulin74–90-derived APL using a CS-directed amino acid modification approach. These prAPL activated TGF-β1 secretion in proinsulin-reactive T cells from PBMC of patients with T1D. We provide evidence that proinsulin-derived prAPL modulate the cytokine signature of proinsulin-reactive T cells at a micromolar range by increasing anti-inflammatory cytokines, including TGF-β1. Thus, the use of prAPL is a promising tool to mitigate autoaggressive T cells.